ALiEM - Pharm Pearls
OCTOBER 30, 2024
Bupe Allergy Buprenorphine induction has been the mainstay of emergency department treatment of opioid use disorder for more than a decade [11, 12]. Of note, screening is often required for insurance approval for substance use treatment. Our experience: Traditionally, ED physicians do not like ordering urine drug screens (UDS).
RX Note
JUNE 21, 2023
Introduction HIV (Human immunodeficiency virus) is an enveloped, single-stranded RNA virus that was recognized as the causative agent of AIDS (acquired immune deficiency syndrome). If HIV is left untreated, the virus will cause progressive weakening of the immune system, a process which occurs at different rates in different people.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
APRIL 25, 2023
In 2022, the global market size of RNAi drug delivery was valued at $69.2B. Even though the company manages to generate a considerable revenue of $21.18M in 2022 through its collaborative agreements, Silence Therapeutics still waiting for the approval of its products. R&D Expenditure: $85.1M R&D Expenditure: $437.9M
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.
Pharmacy Friday Pearls
MARCH 4, 2022
18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.
Putting Patients First Blog
NOVEMBER 12, 2024
Recognizing PrEP as a preventive service rather than as indicative of an active medical condition, as HHS proposes, could help address the current risk selection seen in the market. Clear guidance on the treatment of rebates within the ACF will help avoid distortions in pricing and prevent patients from bearing disproportionate costs.
The Thyroid Pharmacist
JULY 20, 2023
And as we’ve seen, even with supplementation, you need to address your root causes to prevent iron supply and demand challenges. 42] In a smaller 2022 study, 13 non-professional female athletes were evaluated for iron deficiency. Patients on hemodialysis may be prescribed IV or subcutaneous ESAs during dialysis treatments.
Expert insights. Personalized for you.
161 
Let's personalize your content